Program moderator Bruce Feinberg, DO, explains that new drugs for the treatment of cancer hold promise in terms of efficacy; however, these medications come at a high financial cost for patients and payers.
Although the initial drug in a new class of medications is associated with a high price when first released, the price tends to come down substantially when a second drug in the same class is introduced, comments Scott Gottlieb, MD. As an example, he highlights how Sovaldi, a drug for the treatment of hepatitis C, was launched at a high price, and how the price of Sovaldi decreased after the introduction of Harvoni. Dr Gottlieb explains that competition resulting from the entry of additional products that ultimately treat the same underlying disease can affect drug pricing.
Current policies do not often allow second- and third-in-class drugs to enter the market as efficiently as first-in-class drugs, remarks Dr Gottlieb. He notes that the regulatory process for first-in-class drugs is much different from the regulatory process for subsequent drugs. Policy changes that allow subsequent drugs a more favorable entry path could help address concerns regarding drug pricing, suggests Dr Gottlieb.
Higher Life’s Essential 8 Scores Associated With Reduced COPD Risk
November 21st 2024Higher Life’s Essential 8 (LE8) scores, especially those reflecting lower nicotine exposure and better sleep health, are inversely associated with chronic obstructive pulmonary disease (COPD) risk, emphasizing the importance of cardiovascular health (CVH) in disease prevention.
Read More
Study Highlights Key RA-ILD Risk Factors, Urges Early Screening
November 20th 2024This recent study highlights key risk factors for rheumatoid arthritis–associated interstitial lung disease (RA-ILD), emphasizing the importance of early screening to improve diagnosis and patient outcomes.
Read More
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Why Right Heart Catheterization Confirming PAH Diagnosis May Be Underperformed
November 20th 2024Professional guidelines say that when pulmonary arterial hypertension (PAH) is diagnosed, right heart catheterization should be performed, but a quarter of the time, it isn’t—so investigators set out to discover why.
Read More